Greenwich LifeSciences Stock Forecast, Price & News

Greenwich LifeSciences (NASDAQ:GLSI) Frequently Asked Questions

Is Greenwich LifeSciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Greenwich LifeSciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Greenwich LifeSciences stock.
View analyst ratings for Greenwich LifeSciences or view top-rated stocks.

Are investors shorting Greenwich LifeSciences?

Greenwich LifeSciences saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 85,300 shares, a decrease of 21.2% from the October 31st total of 108,300 shares. Based on an average daily trading volume, of 36,300 shares, the days-to-cover ratio is currently 2.3 days. Approximately 3.1% of the company's shares are sold short.
View Greenwich LifeSciences' Short Interest.

What price target have analysts set for GLSI?

2 equities research analysts have issued 1 year price objectives for Greenwich LifeSciences' shares. Their forecasts range from $75.00 to $78.00. On average, they expect Greenwich LifeSciences' stock price to reach $76.50 in the next year. This suggests a possible upside of 131.1% from the stock's current price.
View analysts' price targets for Greenwich LifeSciences or view top-rated stocks among Wall Street analysts.

Who are Greenwich LifeSciences' key executives?

Greenwich LifeSciences' management team includes the following people:

• Ms. Snehal S. Patel, CEO, CFO & Director (Age 57, Pay $507.48k) (LinkedIn Profile)
• Dr. Frank Joseph Daugherty, Chief Medical Officer & Director (Age 70)

Who are some of Greenwich LifeSciences' key competitors?

Some companies that are related to Greenwich LifeSciences include Kadmon (KDMN), Supernus Pharmaceuticals (SUPN), IGM Biosciences (IGMS), Bicycle Therapeutics (BCYC), Verve Therapeutics (VERV), Protagonist Therapeutics (PTGX), ADC Therapeutics (ADCT), Rocket Pharmaceuticals (RCKT), Rani Therapeutics (RANI), Amarin (AMRN), NGM Biopharmaceuticals (NGM), Xenon Pharmaceuticals (XENE), Madrigal Pharmaceuticals (MDGL), Axsome Therapeutics (AXSM) and COMPASS Pathways (CMPS).
View all of GLSI's competitors.

When did Greenwich LifeSciences IPO?

(GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO.

What is Greenwich LifeSciences' stock symbol?

Greenwich LifeSciences trades on the NASDAQ under the ticker symbol "GLSI."

Who are Greenwich LifeSciences' major shareholders?

Greenwich LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Invesco Ltd. (1.14%), Geode Capital Management LLC (0.44%), Millennium Management LLC (0.12%), Tibra Equities Europe Ltd (0.10%), Bank of New York Mellon Corp (0.08%) and OLD Mission Capital LLC (0.06%). Company insiders that own Greenwich LifeSciences stock include Frank Joseph Daugherty and Snehal Patel.
View institutional ownership trends for Greenwich LifeSciences.

Which institutional investors are selling Greenwich LifeSciences stock?

GLSI stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, and California State Teachers Retirement System.
View insider buying and selling activity for Greenwich LifeSciences or view top insider-selling stocks.

Which institutional investors are buying Greenwich LifeSciences stock?

GLSI stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tibra Equities Europe Ltd, OLD Mission Capital LLC, Geode Capital Management LLC, UBS Group AG, Bank of New York Mellon Corp, Jane Street Group LLC, and Royal Bank of Canada. Company insiders that have bought Greenwich LifeSciences stock in the last two years include Frank Joseph Daugherty, and Snehal Patel.
View insider buying and selling activity for Greenwich LifeSciences or or view top insider-buying stocks.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Greenwich LifeSciences' stock price today?

One share of GLSI stock can currently be purchased for approximately $33.10.

How much money does Greenwich LifeSciences make?

Greenwich LifeSciences has a market capitalization of $430.90 million.

How many employees does Greenwich LifeSciences have?

Greenwich LifeSciences employs 2 workers across the globe.

What is Greenwich LifeSciences' official website?

The official website for Greenwich LifeSciences is www.greenwichlifesciences.com.

How can I contact Greenwich LifeSciences?

The company can be reached via phone at 832-819-3232 or via email at [email protected].